Tower Research Capital LLC (Trc) Arcellx, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Arcellx, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 676 shares of ACLX stock, worth $46,515. This represents 0.0% of its overall portfolio holdings.
Number of Shares
676
Previous 4,639
85.43%
Holding current value
$46,515
Previous $256,000
78.13%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ACLX
# of Institutions
204Shares Held
44.1MCall Options Held
2.23MPut Options Held
907K-
Paradigm Biocapital Advisors LP New York, NY4MShares$275 Million12.04% of portfolio
-
Perceptive Advisors LLC New York, NY3.89MShares$268 Million8.48% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$258 Million23.89% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$242 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.46MShares$169 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $3.02B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...